Oncology

Prostate Cancer is a serious disease - Memocore™ helps optimizing the treatment  

According to the WHO's "Global Cancer Facts & Figures 2007" (1) prostate cancer is the second most frequently diagnosed cancer in men with 250,000 deaths yearly.

One treatment modality of prostate cancer is radiotherapy. The development within solid phase physics and computer technology has revolutionized the image diagnostic field and delivery of radiation. The delivery of the radiation can be targeted to the cancer cells and save the normal tissue by moving the beam around the patient (2) delivering a high dose in the middle of the beam - in essence like a magnifying glass and the sun to create fire (Figure 1). 

In external beam radiation therapy (EBRT) the beam is moved around the patient delivering a high dose in the middle of the beam (red), see figure 1.

Placement and use of gold markers currently constitute the golden standard in radiation therapy for prostate cancer. The radiation beam is directed toward the markers.

Memocore™ stent marker (also called the Memocore™ 066) is, however, a more clearly visible 3D marker which facilitates more precise radiotherapy reducing the amount of undesired radiation on healthy tissue and organs at risk while at the same time allowing for higher doses to the cancer cells. This leads to better treatment outcome and a significant reduction of serious side effects.

figure-1-1

One of the key advantages of Memocore™ 066 is visibility in all imaging methods. The gold markers are not ideal because of their small size. Therefore, Memocore™ 066 is a superior marker compared to gold markers.

At figure 2 you can see a co-registered MR and CT scanning. The image is divided into four quadrants. Counting clockwise, the first and third quadrants are the MR image. The second and fourth are the CT image. The stent is seen as a white structure on the CT image and a black line on the MR image. The boundary of the prostate can easily be identified on the MR image (white arrow) while it is difficult to identify on the CT image (3). Fused CT and MR images form the core of optimal outlining of the tissue will be irradiated.

A precise idea of the prostate volume can be obtained via advanced MR techniques combined with advanced software (see figure 3). If only CT is used the size is usually over-estimated.

figure-2-1
figure-3-1

Reference list:
(1)   Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Estimated Number of New Cancer Cases by World Area, 2007. Global Cancer Facts & Figures 2007 2007.
(2)   Carl J, Othel-Jacobsen E. Nitinol Stent - en platforms teknologi til præcisions strålebehandling. MTI 2009;4(6):8-11.
(3)   Carl J, Nielsen J, Holmberg M, Hojkjaer LE, Fabrin K, Fisker RV. A new fiducial marker for Image-guided radiotherapy of prostate cancer: clinical experience. Acta Oncol 2008;47(7):1358-66.